Phaseline

Companies › Saol Therapeutics

Saol Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 3, 1 Phase 2; Immunology, Metabolic and endocrine, Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SL1002–Phase 3Osteoarthritis Knee PainNov 2026
Sodium Dichloroacetate
Pyruvate dehydrogenase kinase inhibitor
PDK2, PDK3, PDK4, PDK1Phase 3Pyruvate Dehydrogenase Complex Deficiency; Glioblastoma Multiforme–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT02616484Sodium DichloroacetatePhase 3Pyruvate Dehydrogenase Complex DeficiencyMetabolic and endocrineAug 2025
NCT05120284Sodium DichloroacetatePhase 2Glioblastoma MultiformeOncologyJul 2026
NCT07226258SL1002Phase 3Osteoarthritis Knee PainImmunologyNov 2026

From the company's SEC filings

Complete response letters from FDA

Targets

PDK2 (1) PDK3 (1) PDK4 (1) PDK1 (1)

Companies with the same targets

–

Companies built like this

Industrial Farmacéutica Cantabria Shandong New Time Pharmaceutical Tolmar Rakuten Medical mAbxience Research

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.